INVESTOR UPDATES AND MEDIA

Date Published By Headline
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call 19 Oct 2020: Audio only
Dr Bill Ketelbey provides an update on the clinical development plans “Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases”
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call 19 Oct 2020: Webcast presentation
Dr Bill Ketelbey provides an update on the clinical development plans “Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases”
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call (19 Oct 2020 at 11.00am AEDT)
19-Oct-20 Bioshares
19-Oct-20 Published by: Bioshares
Edition 865: Actinogen Sets Clear Direction with Capital Raise
15-Oct-20 Biotech Daily
15-Oct-20 Published by: Biotech Daily
Actinogen Up-To $11m Capital Raising For Xanamem Trials
15-Oct-20 The Market Herald
15-Oct-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) to begin two clinical trials, $10.9M capital raise
15-Oct-20 Stockhead
15-Oct-20 Published by: Stockhead
Actinogen reveals its next clinical trial plans
15-Oct-20 Investing.com
15-Oct-20 Published by: Investing.com
BRIEF-Actinogen Medical Announces Two Clinical Trials
13-Oct-20 Financial Review
13-Oct-20 Published by: Financial Review
Bell Potter raising for Alzheimer’s drug hopeful Actinogen
13-Oct-20 The Age
13-Oct-20 Published by: The Age
As it happened: ASX misses 6200, but gains 1%
11.13am Actinogen in trading halt ahead of raise announcement
13-Oct-20 The Market Herald
13-Oct-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) flags future capital raise
29-Sep-20 Biotech Dispatch
29-Sep-20 Published by: Biotech Dispatch
Actinogen Medical announces the appointment of new CFO
08-Sep-20 ASX
08-Sep-20 Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020)
08-Sep-20 ASX
08-Sep-20 Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen Medical (ASX:ACW) pre-recorded presentation with Dr Bill Ketelbey
08-Sep-20 Actinogen Medical
08-Sep-20 Published by: Actinogen Medical
ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen Medical (ASX:ACW) investor presentation
31-Jul-20 Finance News Network
31-Jul-20 Published by: Finance News Network
FNN CEO Showcase: Actinogen Medical (ASX:ACW) Presentation, FNN Online Investor Event, July 2020
28-Jul-20 Finance News Network
28-Jul-20 Published by: Finance News Network
FNN CEO Showcase: Sydney (28 Jul 2020) Virtual Event
27-Jul-20 Alzheimer’s Association
27-Jul-20 Published by: Alzheimer’s Association
Alzheimer’s Association International Conference (AAIC) Virtual Event (27-31 Jul 2020)
17-Jul-20 Innovation Intelligence
17-Jul-20 Published by: Innovation Intelligence
Alzheimer’s treatment could be worth $10bn annually
15-Jun-20 Actinogen Medical
15-Jun-20 Published by: Actinogen Medical
Bio Digital 2020: Company presentation and audio. Dr Bill Ketelbey provides company update “Developing innovative treatments for cognitive impairment associated with neurological and metabolic diseases due to raised cortisol, including Alzheimer’s disease”
08-Jun-20 Biotechnology Innovation Organization
08-Jun-20 Published by: Biotechnology Innovation Organization
BIO Digital 2020: Virtual (8-12 Jun 2020)
08-Jun-20 Actinogen Medical
08-Jun-20 Published by: Actinogen Medical
Bio Digital 2020: Company presentation “Developing innovative treatments for cognitive impairment associated with neurological and metabolic diseases due to raised cortisol, including Alzheimer’s disease”
08-Jun-20 Actinogen Medical
08-Jun-20 Published by: Actinogen Medical
BIO Digital 2020: Company presentation for partnering meetings
29-Apr-20 Actinogen Medical
29-Apr-20 Published by: Actinogen Medical
AAT/AD-PD 2020: Actinogen Full Presentation with Audio presented by Professor Craig Ritchie, Chair of Actinogen’s Xanamem Clinical Advisory Board. Chronically elevated cortisol and cognitive impairment: The therapeutic potential of Xanamem, a potent inhibitor of the 11β-HSD1 enzyme
29-Apr-20 Actinogen Medical
29-Apr-20 Published by: Actinogen Medical
AAT-AD/PD 2020: Actinogen’s Presentation Summary
29-Apr-20 Actinogen Medical
29-Apr-20 Published by: Actinogen Medical
AAT-AD/PD 2020: Actinogen Presentation Only Excluding Audio
02-Apr-20 Kenes Group
02-Apr-20 Published by: Kenes Group
Advances in Alzheimer’s and Parkinson’s Therapies An AAT-AD/PD Focus Meeting: Virtual (2-5 Apr 2020)
29-Jan-20 Sachs TV
29-Jan-20 Published by: Sachs TV
3rd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey, CEO Actinogen Medical Ltd presentation in San Francisco, USA
12-Jan-20 Sachs Associates
12-Jan-20 Published by: Sachs Associates
3rd Annual Nueroscience Innovation Forum: San Francisco USA (12 Jan 2020)
12-Jan-20 Pyschosis Australia Trust
12-Jan-20 Published by: Pyschosis Australia Trust
Australian Psychosis Symposium 2020 (12 Jan 2020)
11-Jan-20 J.P. Morgan
11-Jan-20 Published by: J.P. Morgan
38th Annual Healthcare Conference: San Francisco USA (13-16 Jan 2020)
04-Dec-19 CTAD Congress
04-Dec-19 Published by: CTAD Congress
CTAD 2019 (4-7 Dec 2019)
25-Nov-19 ABC News
25-Nov-19 Published by: ABC News
Dementia and Alzheimer’s disease trials giving patients hope of a better life
25-Nov-19 Actinogen Medical
25-Nov-19 Published by: Actinogen Medical
AGM 2019: Managing Directors Address to Shareholders
25-Nov-19 Actinogen Medical
25-Nov-19 Published by: Actinogen Medical
AGM 2019: Managing Director’s Presentation
25-Nov-19 The New Daily
25-Nov-19 Published by: The New Daily
Dementia and Alzheimer’s disease trials giving patients hope of a better life
22-Nov-19 Edison TV
22-Nov-19 Published by: Edison TV
Executive Interview – Actinogen Medical CEO, Dr Bill Ketelbey, provides an update on recent developments, R&D progress and expected newsflow
19-Nov-19 Actinogen Medical
19-Nov-19 Published by: Actinogen Medical
Investor Newsletter: Nov 2019
08-Nov-19 Stockhead TV
08-Nov-19 Published by: Stockhead TV
90 Seconds with… Actinogen Medical. Dr Bill Ketelbey tells us about his AusBiotech Invest presentation and upcoming newsflow
06-Nov-19 Small Caps
06-Nov-19 Published by: Small Caps
Australian Microcap Investment Conference 2019: Actinogen Medical presentation
31-Oct-19 AusBiotech Investment
31-Oct-19 Published by: AusBiotech Investment
Australia Biotech Invest & Partnering 2019 (31 Oct 2019)
30-Oct-19 AusBiotech
30-Oct-19 Published by: AusBiotech
AusBiotech 2019 (30 Oct – 1 Nov 2019)
30-Oct-19 Boardroom Media
30-Oct-19 Published by: Boardroom Media
ASX:ACW Market update October 2019: Will Canty speaks to Bill Ketelbey at 10th Annual Australian Microcap Investment Conference
27-Oct-19 QUT
27-Oct-19 Published by: QUT
The Bridge Program (27-29 Oct 2019)
27-Oct-19 The Bull.com.au
27-Oct-19 Published by: The Bull.com.au
A Biotech Conference for Stock-Pickers
24-Oct-19 The Market Herald
24-Oct-19 Published by: The Market Herald
Actinogen Medical down 9.3pc despite tax rebate
22-Oct-19 Morgans Financial Limited
22-Oct-19 Published by: Morgans Financial Limited
Under The Microscope Podcast: Morgans Senior Analyst Scott Power interview with Dr Bill Ketelbey explaining recent clinical trial results and the path forward for Xanamem
22-Oct-19 Australian Microcap
22-Oct-19 Published by: Australian Microcap
10th Annual Australian Microcap Investment Conference (22-23 Oct 2019)
11-Oct-19 AC4R
11-Oct-19 Published by: AC4R
Annual Scientific Meeting: Sydney (11 Oct 2019)
09-Oct-19 Bioshares
09-Oct-19 Published by: Bioshares
Edition 812: Actinogen Gets Early Positive Data in Healthy Older Adults with Higher Dose of Xanamem
06-Oct-19 Stockhead
06-Oct-19 Published by: Stockhead
Dr Boreham’s Crucible: Actinogen on the mend after a near-death experience
04-Oct-19 Biotech Daily
04-Oct-19 Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
04-Oct-19 Switzer Daily
04-Oct-19 Published by: Switzer Daily
The Experts: Could these penny dreadfuls become dollar dazzlers?
02-Oct-19 Finfeed
02-Oct-19 Published by: Finfeed
Actinogen’s shares surge 460% after Xanamem success
01-Oct-19 Biotech Daily
01-Oct-19 Published by: Biotech Daily
Actinogen: ‘Xanamem Improves Cognition In Healthy Volunteers’
01-Oct-19 Small Caps
01-Oct-19 Published by: Small Caps
Actinogen Medical announces ‘breakthrough’study results for Alzheimer’s drug Xanamem
01-Oct-19 Stockhead
01-Oct-19 Published by: Stockhead
Health: Actinogen recovers some hope from Xanamem wreckage
01-Oct-19 Pharmaceutical Daily News
01-Oct-19 Published by: Pharmaceutical Daily News
Actinogen Medical pleased with positive efficacy data for Xanamem in Alzheimer’s patients
01-Oct-19 Motley Fool
01-Oct-19 Published by: Motley Fool
Why Actinogen Medical shares climbed 466% on excitement over an Alzheimer’s treatment
01-Oct-19 Actinogen Medical
01-Oct-19 Published by: Actinogen Medical
Conference Call Audio: 1 Oct 2019 Cognitive improvement demonstrated with Xanamem
25-Sep-19 Alzheimer’s Association
25-Sep-19 Published by: Alzheimer’s Association
AAIC Satellite Sydney Symposium: Sydney (25-27 Sep 2019)
25-Sep-19 Actinogen Medical
25-Sep-19 Published by: Actinogen Medical
AAIC Satellite Symposium: Poster Presentation. Chronically Elevated Cortisol and Cognitive Impairment: The Therapeutic Potential of Xanamem™, a Potent Inhibitor of the 11β-HSD1 Enzyme
19-Aug-19 Informa Connect
19-Aug-19 Published by: Informa Connect
Bio Connections Australia: Melbourne (19-20 Aug 2019)
26-Jul-19 Bioshares
26-Jul-19 Published by: Bioshares
2019 Bioshares Biotech Summit: Queenstown NZ (26-27 Jul 2019)
03-Jul-19 Boardroom Media
03-Jul-19 Published by: Boardroom Media
ASX:ACW Xanamem Clinical Development & Investor Update
29-Jun-19 Finfeed
29-Jun-19 Published by: Finfeed
Cortisol inhibition – a potential new approach to treating Alzheimer’s disease
26-Jun-19 Actinogen Medical
26-Jun-19 Published by: Actinogen Medical
Investor Presentation Jun 2019: A novel approach to treating cognitive impairment and Alzheimer’s disease
03-Jun-19 Bioshares
03-Jun-19 Published by: Bioshares
Edition 794: Actinogen Medical – Update on Higher Dose Safety Study
03-Jun-19 Biotechnology Innovation Organization
03-Jun-19 Published by: Biotechnology Innovation Organization
Bio 2019, Philadelphia, USA (3-6 Jun 2019)
13-May-19 Bioshares
13-May-19 Published by: Bioshares
Edition 791: Actinogen – Phase II Study Dose Too Low
07-May-19 The World News
07-May-19 Published by: The World News
Actinogen shares crash after drug trial
07-May-19 nine.com.au Finance
07-May-19 Published by: nine.com.au Finance
Actinogen shares crash after drug trial
07-May-19 The Motley Fool
07-May-19 Published by: The Motley Fool
Actinogen Medical share price crashes 67% lower on Alzheimer’s study results
07-May-19 Investing.com
07-May-19 Published by: Investing.com
BRIEF-Actinogen Medical Updates On Phase II Alzheimer’s Disease Trial Results
07-May-19 NT News
07-May-19 Published by: NT News
Actinogen shares crash after drug trial
07-May-19 Mercury
07-May-19 Published by: Mercury
Actinogen shares crash after drug trial
07-May-19 Herald Sun
07-May-19 Published by: Herald Sun
Actinogen shares crash after drug trial
07-May-19 Kalkine Media
07-May-19 Published by: Kalkine Media
Actinogen Medical Released Alzheimer’s Disease Trial
07-May-19 Small Caps
07-May-19 Published by: Small Caps
Actinogen Medical phase two Alzheimer’s clinical trial disappoints
07-May-19 Biotech Dispatch
07-May-19 Published by: Biotech Dispatch
XanADu trial disappoints for Actinogen Medical
07-May-19 Stockhead
07-May-19 Published by: Stockhead
Health: Actinogen’s Alzheimer’s treatment comes up short, stock crashes 70pc
07-May-19 Yahoo Finance
07-May-19 Published by: Yahoo Finance
Actinogen Medical share price crashes 67% lower on Alzheimer’s study results
07-May-19 news.com.au
07-May-19 Published by: news.com.au
Actinogen shares crash after drug trial
07-May-19 Alzheimer Europe
07-May-19 Published by: Alzheimer Europe
Actinogen Medical announces results from its Phase II clinical trial XanADu in AD
16-Apr-19 Actinogen Medical
16-Apr-19 Published by: Actinogen Medical
Investor Newsletter: Apr 2019
14-Apr-19 The Today Show
14-Apr-19 Published by: The Today Show
Alzheimer’s breakthrough: New drug targets cortisol, the stress hormone in the brain
09-Apr-19 News.com.au
09-Apr-19 Published by: News.com.au
Aussie pill could hold cure for Alzheimer’s
08-Apr-19 7 News
08-Apr-19 Published by: 7 News
Alzheimer’s breakthrough could be just a pill away after medical trial in Perth
08-Apr-19 The West Australian
08-Apr-19 Published by: The West Australian
Perth trial gives hope for Alzheimer’s breakthrough
08-Apr-19 Perth Now
08-Apr-19 Published by: Perth Now
Perth trial gives hope for Alzheimer’s breakthrough
04-Apr-19 Biotech Dispatch
04-Apr-19 Published by: Biotech Dispatch
Actinogen appoints new director
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Video: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Podcast: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
25-Mar-19 Bioshares
25-Mar-19 Published by: Bioshares
A Local Investment Perspective
20-Mar-19 Edison TV
20-Mar-19 Published by: Edison TV
Executive Interview with Dr Bill Ketelbey, CEO, Actinogen Medical
18-Mar-19 PharmiWeb.com
18-Mar-19 Published by: PharmiWeb.com
Edison initiates coverage on Actinogen Medical (ACW)
01-Mar-19 Neuro Central
01-Mar-19 Published by: Neuro Central
International Women’s Day: A day in the life of Tamara Miller
22-Feb-19 Boardroom Media
22-Feb-19 Published by: Boardroom Media
1st participant dosed in important new Xanamem study-XanaHES
30-Jan-19 BioWorld
30-Jan-19 Published by: BioWorld
Australian’s Actinogen tackles Alzheimer’s disease by inhibiting excess cortisol in the brain
07-Jan-19 J.P. Morgan
07-Jan-19 Published by: J.P. Morgan
37th Annual J.P. Morgan Healthcare Conference San Francisco USA (7-10 Jan 2019)
06-Jan-19 Sachs Associates
06-Jan-19 Published by: Sachs Associates
2nd Annual SACHS Neuroscience Innovation Forum San Francisco USA (6 Jan 2019)
06-Jan-19 Actinogen Medical
06-Jan-19 Published by: Actinogen Medical
Investor Presentation Jan 2019: Presentation at Sachs Neuroscience Innovation Forum during JPM Week
06-Jan-19 Sachs TV
06-Jan-19 Published by: Sachs TV
2nd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey presentation in San Francisco, USA
04-Jan-19 Stockhead
04-Jan-19 Published by: Stockhead
Actinogen in the Stockhead 1000+ club – one of only six small cap healthcare companies to grow more than 1000 percent over the last decade
18-Dec-18 Cognitive Vitality
18-Dec-18 Published by: Cognitive Vitality
Does stress worsen cognitive functions?
12-Dec-18 Actinogen Medical
12-Dec-18 Published by: Actinogen Medical
Investor Newsletter: Dec 2018
08-Dec-18 The West Australian
08-Dec-18 Published by: The West Australian
Trial drug offers hope for Alzheimer’s treatment
28-Nov-18 Actinogen Medical
28-Nov-18 Published by: Actinogen Medical
AGM: Managing Director’s Presentation 2018
28-Nov-18 Actinogen Medical
28-Nov-18 Published by: Actinogen Medical
Actinogen Medical XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Actinogen has achieved a major milestone through enrolling the final patient into XanADu, its landmark trial in Alzheimer’s disease. Find out more on XanADu, and Xanamem and cortisol in Alzheimer’s and other neurological diseases, with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board.
27-Nov-18 Biotech Dispatch
27-Nov-18 Published by: Biotech Dispatch
Final patient enrolled in Actinogen’s XanADu trial
26-Nov-18 Business Wire
26-Nov-18 Published by: Business Wire
Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting Stress Hormone Cortisol
26-Nov-18 Actinogen Medical
26-Nov-18 Published by: Actinogen Medical
Investor Presentation Nov 2018: A novel approach to treating cognitive impairment and Alzheimer’s disease
25-Nov-18 Alzheimer Europe Science Watch
25-Nov-18 Published by: Alzheimer Europe Science Watch
Actinogen Medical completes recruitment of participants for its Phase II clinical trial of Xanamem for AD
20-Nov-18 Australian Financial Review (AFR)
20-Nov-18 Published by: Australian Financial Review (AFR)
Developing potential Alzheimer’s treatment
Investors eye new drug’s possibilities
01-Nov-18 BioPharma Dealmakers
01-Nov-18 Published by: BioPharma Dealmakers
Targeting cortisol to treat Alzheimer’s disease and cognitive impairment
01-Nov-18 Proactive Investors
01-Nov-18 Published by: Proactive Investors
Actinogen moves to next stage of Alzheimer’s treatment trials
31-Oct-18 Ch 9 News Online
31-Oct-18 Published by: Ch 9 News Online
Cortisol-blocking drug could slow Alzheimer’s
Actinogen Medical and Xanamem featured on national TV referencing our XanADu trial in Alzheimer’s disease. The trial has recruited the last patient and is on track to report out results in less than 8 months!
31-Oct-18 Ch 9 News
31-Oct-18 Published by: Ch 9 News
Stress could lead to dementia
Actinogen Medical and Xanamem featured on national TV referencing our XanADu trial in Alzheimer’s disease. The trial has recruited the last patient and is on track to report out results in less than 8 months!
30-Oct-18 Actinogen Medical
30-Oct-18 Published by: Actinogen Medical
Australia Biotech Invest & Partnering 2018: Oct 2018
24-Oct-18 CTAD Congress
24-Oct-18 Published by: CTAD Congress
CTAD Barcelona, Spain (24-27 Oct 2018)
17-Oct-18 Australian Microcap
17-Oct-18 Published by: Australian Microcap
Australian Microcap Investment Conference Melbourne, Australia (17 Oct 2018)
17-Oct-18 Actinogen Medical
17-Oct-18 Published by: Actinogen Medical
Australian Microcap Investment Conference Oct 2018: A novel approach to treating cognitive impairment and Alzheimer’s disease
12-Oct-18 AC4R
12-Oct-18 Published by: AC4R
Annual Scientific Meeting Sydney, Australia (12 Oct 2018)
12-Oct-18 Spark Plus
12-Oct-18 Published by: Spark Plus
Healthcare Investor Day
10-Oct-18 AusBiotech Investment
10-Oct-18 Published by: AusBiotech Investment
Australia Biotech Invest & Partnering, Melbourne (30 Oct 2018)
01-Oct-18 Aged Care Weekly
01-Oct-18 Published by: Aged Care Weekly
Dispelling myths about Alzheimer’s disease
25-Sep-18 Finance News Network
25-Sep-18 Published by: Finance News Network
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
25-Sep-18 FNN Investor Event
25-Sep-18 Published by: FNN Investor Event
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
19-Sep-18 The Constant Investor
19-Sep-18 Published by: The Constant Investor
A biotech all about Alzheimer’s
18-Sep-18 Finance News Network
18-Sep-18 Published by: Finance News Network
FNN Investor Event, Sydney Australia (18 Sep 2018)
12-Sep-18 Spark Plus
12-Sep-18 Published by: Spark Plus
Healthcare Investor Day, Singapore (12 Sep 2018)
12-Sep-18 Actinogen Medical
12-Sep-18 Published by: Actinogen Medical
Investor Fact Sheet: Sep 2018
12-Sep-18 Actinogen Medical
12-Sep-18 Published by: Actinogen Medical
Singapore Healthcare Investor Day Sep 2018: Alzheimer’s Treatment Needs a New Approach – Xanamem
10-Sep-18 Aged Care Weekly
10-Sep-18 Published by: Aged Care Weekly
How do we prepare for Dementia and Alzheimer’s?
07-Sep-18 Talking Business
07-Sep-18 Published by: Talking Business
Ep 30: Podcast interview with Leon Gettler & Dr Bill Ketelbey (Play from 1:00 to 16.50)
05-Sep-18 Stockhead
05-Sep-18 Published by: Stockhead
Why Actinogen’s progress is good news for Alzheimer’s patients and investors
16-Aug-18 Pharma In Focus
16-Aug-18 Published by: Pharma In Focus
Australian Alzheimer drug progresses
15-Aug-18 LabOnline
15-Aug-18 Published by: LabOnline
Patient enrolment for Alzheimer’s trial close to completion
15-Aug-18 Stockhead
15-Aug-18 Published by: Stockhead
Actinogen Hits Enrolment Milestone for Alzheimer’s Treatment Clinical Trial
09-Aug-18 Biotech Dispatch
09-Aug-18 Published by: Biotech Dispatch
Recognition for Actinogen Medical advisor
08-Aug-18 Actinogen Medical
08-Aug-18 Published by: Actinogen Medical
Advisory Board Member Receives Lifetime Achievement Award: Prof Jeffrey Cummings M.D. Sc.D. awarded a Lifetime Achievement Award from the American Alzheimer’s Association at AAIC 2018
30-Jul-18 Stockhead
30-Jul-18 Published by: Stockhead
Actinogen to expand clinical development program of its novel Alzheimer’s drug
27-Jul-18 Bioshares
27-Jul-18 Published by: Bioshares
Bioshares Biotech Summit 2018 Queenstown, NZ (27-28 Jul 2018)
22-Jul-18 Alzheimer’s Association
22-Jul-18 Published by: Alzheimer’s Association
AAIC 2018 Chicago, USA (22-26 Jul 2018)
12-Jul-18 Stockhead
12-Jul-18 Published by: Stockhead
Actinogen is amping up patient recruitment for faster testing of novel Alzheimer’s drug
11-Jul-18 BBC News
11-Jul-18 Published by: BBC News
Dementia app firm MindMate teams up for clinical trial
11-Jul-18 Digit
11-Jul-18 Published by: Digit
MindMate Partners with Actinogen to Pioneer Alzheimer’s Research
03-Jul-18 Aged Care Weekly
03-Jul-18 Published by: Aged Care Weekly
Participating in clinical research benefits the individual and society as a whole
28-Jun-18 CommSec Executive Series
28-Jun-18 Published by: CommSec Executive Series
Dr Bill Ketelbey speaks with Tom Piotrowski about the company’s Ph II clinical trial for the treatment of Alzheimer’s disease
07-Jun-18 Stockhead
07-Jun-18 Published by: Stockhead
Actinogen presents Alzheimer’s trial data and more at world’s biggest biotech event
06-Jun-18 Proactive Investors
06-Jun-18 Published by: Proactive Investors
Actinogen Medical opens SPP after successful $15 million placement
04-Jun-18 Actinogen Medical
04-Jun-18 Published by: Actinogen Medical
BIO International Convention Jun 2018: Presentation ‘Alzheimer’s Treatment Needs a New Approach – Xanamem’
04-Jun-18 Biotechnology Innovation Organization
04-Jun-18 Published by: Biotechnology Innovation Organization
BIO International Convention Boston, USA (4-7 Jun 2018)
31-May-18 Proactive Investors
31-May-18 Published by: Proactive Investors
Actinogen Medical presenting success with Xanamem at BIO International
30-May-18 Open Briefing
30-May-18 Published by: Open Briefing
Investor Conference Call Transcript: 30 May 2018
30-May-18 Actinogen Medical
30-May-18 Published by: Actinogen Medical
Investor Conference Call Audio: 30 May 2018
30-May-18 Aged Care Weekly
30-May-18 Published by: Aged Care Weekly
Xanamem drug: A step forward for Alzheimer’s disease
28-May-18 Actinogen Medical
28-May-18 Published by: Actinogen Medical
Investor Presentation: May/Jun 2018
24-May-18 Biotech Dispatch
24-May-18 Published by: Biotech Dispatch
Positive news for Australian company Actinogen
24-May-18 SkyNews.com.au
24-May-18 Published by: SkyNews.com.au
Business | Tech.Biz | VIEW FROM 16:49
Actinogen Medical announces $15 million capital raise
23-May-18 Small Caps
23-May-18 Published by: Small Caps
Actinogen Medical attracts US biotech investor as Alzheimer’s XanADu study remains on track
23-May-18 Business News Australia
23-May-18 Published by: Business News Australia
Alzheimer’s research company secures capital raising on promising trials
23-May-18 Rat’s Rant
23-May-18 Published by: Rat’s Rant
The Mafia Edition
23-May-18 The Australian
23-May-18 Published by: The Australian
Actinogen wins backing for Alzheimer’s treatment trial
23-May-18 Stockhead
23-May-18 Published by: Stockhead
Actinogen’s Alzheimer’s trial gets independent tick of approval; raises $15m
14-May-18 Stockhead
14-May-18 Published by: Stockhead
Blockchain could be a game changer in medical clinical trials, says top expert
13-May-18 Daily Mail
13-May-18 Published by: Daily Mail
Being a medical guinea pig could help Alzheimer’s patients stay a step ahead of the memory robbing disease
08-May-18 Aged Care Weekly
08-May-18 Published by: Aged Care Weekly
Have we been looking at Alzheimer’s disease the wrong way?
02-May-18 Proactive Investors
02-May-18 Published by: Proactive Investors
Actinogen Medical attracts $15 million to progress Alzheimer’s disease therapy
19-Apr-18 Stockhead
19-Apr-18 Published by: Stockhead
Alzheimer’s treatment failures are an opportunity for Actinogen
05-Apr-18 Actinogen Medical
05-Apr-18 Published by: Actinogen Medical
Investor Open Briefing March 2018: Dr Bill Ketelbey, CEO, and Dr Geoff Brooke, Chairman, presented at the Investor Briefing in Sydney providing an update on Actinogen Medical and the exciting developments with Xanamem in Alzheimer’s disease
23-Mar-18 The Age
23-Mar-18 Published by: The Age
What if we have got it wrong on Alzheimer’s?
23-Mar-18 The Sydney Morning Herald
23-Mar-18 Published by: The Sydney Morning Herald
What if we have got it wrong on Alzheimer’s?
21-Mar-18 Small Caps
21-Mar-18 Published by: Small Caps
Actinogen moves towards XanADu starting line to treat Alzheimer’s disease
21-Mar-18 Stockhead
21-Mar-18 Published by: Stockhead
Major Milestone: Actinogen’s Alzheimer’s trial passes half-way point
19-Mar-18 Actinogen Medical
19-Mar-18 Published by: Actinogen Medical
Presentation: Investor Open Briefing: Mar 2018: Alzheimer Treatment Needs a New Approach – Xanamem
16-Mar-18 Aged Care Weekly
16-Mar-18 Published by: Aged Care Weekly
Things you didn’t know about your brain
27-Feb-18 Daily Mail
27-Feb-18 Published by: Daily Mail
Could anti-stress drug help beat Alzheimers? Scientists have failed to find a treatment for the disease after decades of research
19-Feb-18 Stockhead
19-Feb-18 Published by: Stockhead
Actinogen on track with Alzheimer’s trial as research falls into line
16-Feb-18 Rat’s Rant
16-Feb-18 Published by: Rat’s Rant
What’s Doing
12-Feb-18 Rat’s Rant
12-Feb-18 Published by: Rat’s Rant
What’s Hot
12-Feb-18 Stockhead
12-Feb-18 Published by: Stockhead
Aussie biotech Actinogen is testing a unique treatment for Alzheimer’s
06-Feb-18 Biotech Daily
06-Feb-18 Published by: Biotech Daily
ACW: Research Backs Stress, Cognitive Decline Link
29-Jan-18 Stockhead
29-Jan-18 Published by: Stockhead
Actinogen hopes Alzheimer’s trial can beat global 99.6pc failure rate
25-Jan-18 Biotech Daily
25-Jan-18 Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
08-Jan-18 J.P. Morgan
08-Jan-18 Published by: J.P. Morgan
J.P. Morgan Healthcare Conference San Francisco USA (8-11 Jan 2018)
04-Jan-18 The West Australian
04-Jan-18 Published by: The West Australian
Researchers confident stress drug could be Alzheimer’s breakthrough
09-Dec-17 The Mercury
09-Dec-17 Published by: The Mercury
Talking Point: The more drugs we trial, the closer we get
08-Dec-17 nestegg.com.au
08-Dec-17 Published by: nestegg.com.au
‘Alarm call’: dementia incidences to triple by 2050
06-Dec-17 Australian Financial Review
06-Dec-17 Published by: Australian Financial Review
Actinogen Medical raises $5.2m for Alzheimer’s treatment
29-Nov-17 Actinogen Medical
29-Nov-17 Published by: Actinogen Medical
AGM: Managing Director’s Presentation 2017
29-Nov-17 Actinogen Medical
29-Nov-17 Published by: Actinogen Medical
Actinogen Medical & KaRa Minds: Leading Alzheimer’s Researchers Address to Shareholders
Dr Bill Ketelbey speaks with Prof Ralph Martins and Associate Prof Kathryn Goozee from KaRa Minds following the Actinogen Medical AGM
28-Nov-17 Ted.com
28-Nov-17 Published by: Ted.com
Elizabeth Blackburn at TED2017: The science of cells that never get old
09-Nov-17 The Motley Fool
09-Nov-17 Published by: The Motley Fool
2 exciting biotech shares to watch in 2018
07-Nov-17 Biotech Dispatch
07-Nov-17 Published by: Biotech Dispatch
Amgen veteran joins Actinogen
31-Oct-17 Australasian Biotechnology
31-Oct-17 Published by: Australasian Biotechnology
The Journal of AusBiotech | Oct 2017 | Vol 27 | Number 3: A new approach to Alzheimer’s disease
31-Oct-17 The Senior
31-Oct-17 Published by: The Senior
What will it take to find a cure for Alzheimer’s disease?
26-Oct-17 Aged Care Insite
26-Oct-17 Published by: Aged Care Insite
Why we need new treatments to beat Alzheimer’s
25-Oct-17 AusBiotech
25-Oct-17 Published by: AusBiotech
AusBiotech 2017 Adelaide, Australia (25-27 Oct 2017)
24-Oct-17 AusBiotech Investment
24-Oct-17 Published by: AusBiotech Investment
Australia Biotech Invest 2017 Melbourne, Australia (24 Oct 2017)
24-Oct-17 Hot Copper / BIG Business News & Finance
24-Oct-17 Published by: Hot Copper / BIG Business News & Finance
Australian Microcap Investment Conference: Interview with Dr Bill Ketelbey
17-Oct-17 AAIC
17-Oct-17 Published by: AAIC
Alzheimer’s Australia Biennial National Dementia Conference Melbourne, Australia (17-20 Oct 2017)
17-Oct-17 Australian Microcap
17-Oct-17 Published by: Australian Microcap
8th Annual Australian Microcap Investment Melbourne, Australia (17-18 Oct 2017)
17-Oct-17 AC4R
17-Oct-17 Published by: AC4R
AC4R Conference Melbourne, Australia (17 Oct 2017)
16-Oct-17 Actinogen Medical
16-Oct-17 Published by: Actinogen Medical
Investor Presentation: Oct 2017
16-Oct-17 Actinogen Medical
16-Oct-17 Published by: Actinogen Medical
Investor Fact Sheet: Oct 2017
12-Oct-17 Actinogen Medical
12-Oct-17 Published by: Actinogen Medical
Investor Newsletter: October 2017
08-Sep-17 Actinogen Medical
08-Sep-17 Published by: Actinogen Medical
Investor Fact Sheet: Sep 2017
21-Jul-17 Bioshares
21-Jul-17 Published by: Bioshares
Bioshares Biotech 2017 Summit Queenstown, NZ (21-22 Jul 2017)
09-Jul-17 Channel 9 News National
09-Jul-17 Published by: Channel 9 News National
Breakthrough Alzheimer’s medication could ‘make a difference’ in just three months
09-Jul-17 Sunday Times Perth
09-Jul-17 Published by: Sunday Times Perth
Crucial WA Test: Is this the Alzheimer’s breakthrough the world has been waiting for?
22-Jun-17 9 Finance: Business News
22-Jun-17 Published by: 9 Finance: Business News
Actinogen enrols US patients for XanADu
19-Jun-17 Biotechnology Innovation Organization
19-Jun-17 Published by: Biotechnology Innovation Organization
Bio International Convention San Diego, USA (19-22 Jun 2017)
23-May-17 Lab Online
23-May-17 Published by: Lab Online
Blocking the stress hormone: Phase II Alzheimer’s trial underway
22-May-17 ABC Central
22-May-17 Published by: ABC Central
First patient from Central Coast
18-May-17 Biotech Dispatch
18-May-17 Published by: Biotech Dispatch
Actinogen Medical starts Phase 2 trial for Alzheimer’s therapy
17-May-17 Pharmacy Daily
17-May-17 Published by: Pharmacy Daily
Xanamem AD trials
16-May-17 Proactive Investors
16-May-17 Published by: Proactive Investors
Actinogen Medical begins landmark Alzheimer’s disease clinical trial
16-May-17 Biotech Daily
16-May-17 Published by: Biotech Daily
Actinogen Treats 1st Xanamem Alzheimer’s Patient
10-May-17 The Daily Edition
10-May-17 Published by: The Daily Edition
Alzheimer’s trial targeting stress hormone
10-May-17 The Australian Financial Review (AFR)
10-May-17 Published by: The Australian Financial Review (AFR)
Australian Firm Treads New Path On Alzheimer’s
27-Mar-17 Actinogen Medical
27-Mar-17 Published by: Actinogen Medical
Investor Presentation: March 2017
27-Mar-17 Herald Sun
27-Mar-17 Published by: Herald Sun
New trial offers hope on dementia
27-Mar-17 The West Australian
27-Mar-17 Published by: The West Australian
Human drug trial key to beat Alzheimer’s
27-Mar-17 The Daily Telegraph
27-Mar-17 Published by: The Daily Telegraph
Trial go-ahead for new Alzheimer’s drug
27-Mar-17 The Advertiser
27-Mar-17 Published by: The Advertiser
Dementia drug trial will give new hope
27-Mar-17 Geelong Advertiser
27-Mar-17 Published by: Geelong Advertiser
Trial to test promising drug for treating Alzheimer’s disease
27-Mar-17 Townsville Bulletin
27-Mar-17 Published by: Townsville Bulletin
Alzheimer’s drug hope
27-Mar-17 The Mercury
27-Mar-17 Published by: The Mercury
Drug trial starts to tackle one of nation’s biggest killers
27-Mar-17 NT News
27-Mar-17 Published by: NT News
Trial for new Alzheimer’s pill
27-Mar-17 Gold Coast Bulletin
27-Mar-17 Published by: Gold Coast Bulletin
New drug offers hope
26-Mar-17 Herald Sun
26-Mar-17 Published by: Herald Sun
‘Blockbuster’ Alzheimer’s drug Xanamem to be tested on Australian patients
16-Mar-17 Actinogen Medical
16-Mar-17 Published by: Actinogen Medical
Quarterly Newsletter: Mar 2017
07-Feb-17 British Journal of Pharmacology: Research Paper
07-Feb-17 Published by: British Journal of Pharmacology: Research Paper
Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)
01-Feb-17 Actinogen Medical
01-Feb-17 Published by: Actinogen Medical
Professor Colin Masters receives Australia Day Honours
30-Nov-16 Actinogen Medical
30-Nov-16 Published by: Actinogen Medical
AGM Presentation 2016
24-Oct-16 AusBiotech
24-Oct-16 Published by: AusBiotech
AusBiotech 2016 Melbourne, Australia (24-27 Oct 2016)
29-Sep-16 Wholesale Investor
29-Sep-16 Published by: Wholesale Investor
Dr Bill Ketelbey Interview
26-Sep-16 The World Loves Melbourne
26-Sep-16 Published by: The World Loves Melbourne
Understanding Alzheimer’s Conference at Novotel Melbourne
31-Aug-16 Actinogen Medical
31-Aug-16 Published by: Actinogen Medical
Investor Update: Issue 5
24-Aug-16 NextBiotech
24-Aug-16 Published by: NextBiotech
ACW Starts Phase II Clinical Trials: Major Milestone Set to Unlock Value Uplift?
29-Jul-16 Herald Sun
29-Jul-16 Published by: Herald Sun
Australian Drug to be trialled in bid to stop Alzheimer’s disease
28-Jul-16 Bioshares
28-Jul-16 Published by: Bioshares
BioShares Biotechnology Summit Queenstown, NZ (28-29 Jul 2016)
28-Jul-16 IT Wire
28-Jul-16 Published by: IT Wire
Aussie company developing ‘landmark’ drug as potential treatment for Alzheimer’s
28-Jul-16 The Australian
28-Jul-16 Published by: The Australian
Alzheimer’s research offers hope
27-Jul-16 BusinessWire
27-Jul-16 Published by: BusinessWire
Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer’s Disease
22-Jul-16 Alzheimer’s Association
22-Jul-16 Published by: Alzheimer’s Association
AAIC Toronto, Canada (22-28 Jul 2016)
08-Jun-16 FinFeed
08-Jun-16 Published by: FinFeed
FDA Feedback puts Actinogen’s phase II trial one step closer to US approval
08-Jun-16 NextBiotech
08-Jun-16 Published by: NextBiotech
Multi-Billion Alzheimer’s Drug Development Boom Underway: ACW Well Positioned in Phase II Trials
08-Jun-16 BioTech Daily
08-Jun-16 Published by: BioTech Daily
FDA Enhances Phase II Xanamem Alzheimer’s Trial
08-Jun-16 Wholesale Investor
08-Jun-16 Published by: Wholesale Investor
Actinogen Receives US FDA Feedback to Enhance Alzheimers Study
31-May-16 AC4R
31-May-16 Published by: AC4R
AC4R Conference Cairns, Australia (31 May 2016)
10-May-16 EBD Group
10-May-16 Published by: EBD Group
BioEquity Copenhagen, Denmark (10-11 May 2016)
06-May-16 Wholesale Investor
06-May-16 Published by: Wholesale Investor
WI Small Cap Showcase Sydney, Australia (6 May 2016)
20-Apr-16 NextBiotech
20-Apr-16 Published by: NextBiotech
Ex Pfizer VP to Repeat Market Topping Drug Development with this ASX stock?
10-Mar-16 Actinogen Medical
10-Mar-16 Published by: Actinogen Medical
Investor Presentation: Developing Xanamem for Alzheimer’s disease – Cortisol Hypothesis: March 2016
01-Dec-15 Actinogen Medical
01-Dec-15 Published by: Actinogen Medical
Investor Update: Issue 4
18-Nov-15 Finance News Network
18-Nov-15 Published by: Finance News Network
Actinogen discusses Xanamem Phase 1 results
12-Nov-15 Actinogen Medical
12-Nov-15 Published by: Actinogen Medical
AGM Presentation 2015
06-Oct-15 Proactive Investors
06-Oct-15 Published by: Proactive Investors
Actinogen Medical on track with Alzheimer’s Drug
28-Sep-15 Proactive Investors
28-Sep-15 Published by: Proactive Investors
Actinogen readies to reveal clinical data
17-Aug-15 Actinogen Medical
17-Aug-15 Published by: Actinogen Medical
Investor Update: Issue 3
01-May-15 AFR
01-May-15 Published by: AFR
Alzheimer’s cure behind the boom in brain science
27-Apr-15 Herald Sun
27-Apr-15 Published by: Herald Sun
Victorian trial to treat early-stage Alzheimer’s by reducing brain’s stress hormone levels
24-Apr-15 Proactive Investors
24-Apr-15 Published by: Proactive Investors
Actinogen Medical raises $10M for Alzheimer’s drug trial
15-Apr-15 Actinogen Medical
15-Apr-15 Published by: Actinogen Medical
Investor Update: Issue 2
14-Apr-15 Open Briefing
14-Apr-15 Published by: Open Briefing
Xanamem™ Clinical Advisory Board Conference Call Transcript
14-Apr-15 Open Briefing
14-Apr-15 Published by: Open Briefing
Xanamem™ Clinical Advisory Board Conference Call Recording
13-Apr-15 Actinogen Medical
13-Apr-15 Published by: Actinogen Medical
Investor Presentation: Developing Xanamem™ for Alzheimer’s Dementia: April 2015
09-Mar-15 Actinogen Medical
09-Mar-15 Published by: Actinogen Medical
Investor Presentation: Developing Xanamem™ for Alzheimer’s Dementia: March 2015
16-Feb-15 Actinogen Medical
16-Feb-15 Published by: Actinogen Medical
Investor Update: Issue 1
Date Published By Headline
19-Oct-20 Bioshares
19-Oct-20 Published by: Bioshares
Edition 865: Actinogen Sets Clear Direction with Capital Raise
15-Oct-20 Biotech Daily
15-Oct-20 Published by: Biotech Daily
Actinogen Up-To $11m Capital Raising For Xanamem Trials
15-Oct-20 The Market Herald
15-Oct-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) to begin two clinical trials, $10.9M capital raise
15-Oct-20 Stockhead
15-Oct-20 Published by: Stockhead
Actinogen reveals its next clinical trial plans
15-Oct-20 Investing.com
15-Oct-20 Published by: Investing.com
BRIEF-Actinogen Medical Announces Two Clinical Trials
13-Oct-20 Financial Review
13-Oct-20 Published by: Financial Review
Bell Potter raising for Alzheimer’s drug hopeful Actinogen
13-Oct-20 The Age
13-Oct-20 Published by: The Age
As it happened: ASX misses 6200, but gains 1%
11.13am Actinogen in trading halt ahead of raise announcement
13-Oct-20 The Market Herald
13-Oct-20 Published by: The Market Herald
Actinogen Medical (ASX:ACW) flags future capital raise
29-Sep-20 Biotech Dispatch
29-Sep-20 Published by: Biotech Dispatch
Actinogen Medical announces the appointment of new CFO
08-Sep-20 ASX
08-Sep-20 Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen Medical (ASX:ACW) pre-recorded presentation with Dr Bill Ketelbey
31-Jul-20 Finance News Network
31-Jul-20 Published by: Finance News Network
FNN CEO Showcase: Actinogen Medical (ASX:ACW) Presentation, FNN Online Investor Event, July 2020
17-Jul-20 Innovation Intelligence
17-Jul-20 Published by: Innovation Intelligence
Alzheimer’s treatment could be worth $10bn annually
25-Nov-19 ABC News
25-Nov-19 Published by: ABC News
Dementia and Alzheimer’s disease trials giving patients hope of a better life
25-Nov-19 The New Daily
25-Nov-19 Published by: The New Daily
Dementia and Alzheimer’s disease trials giving patients hope of a better life
06-Nov-19 Small Caps
06-Nov-19 Published by: Small Caps
Australian Microcap Investment Conference 2019: Actinogen Medical presentation
30-Oct-19 Boardroom Media
30-Oct-19 Published by: Boardroom Media
ASX:ACW Market update October 2019: Will Canty speaks to Bill Ketelbey at 10th Annual Australian Microcap Investment Conference
27-Oct-19 The Bull.com.au
27-Oct-19 Published by: The Bull.com.au
A Biotech Conference for Stock-Pickers
24-Oct-19 The Market Herald
24-Oct-19 Published by: The Market Herald
Actinogen Medical down 9.3pc despite tax rebate
09-Oct-19 Bioshares
09-Oct-19 Published by: Bioshares
Edition 812: Actinogen Gets Early Positive Data in Healthy Older Adults with Higher Dose of Xanamem
06-Oct-19 Stockhead
06-Oct-19 Published by: Stockhead
Dr Boreham’s Crucible: Actinogen on the mend after a near-death experience
04-Oct-19 Biotech Daily
04-Oct-19 Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
04-Oct-19 Switzer Daily
04-Oct-19 Published by: Switzer Daily
The Experts: Could these penny dreadfuls become dollar dazzlers?
02-Oct-19 Finfeed
02-Oct-19 Published by: Finfeed
Actinogen’s shares surge 460% after Xanamem success
01-Oct-19 Biotech Daily
01-Oct-19 Published by: Biotech Daily
Actinogen: ‘Xanamem Improves Cognition In Healthy Volunteers’
01-Oct-19 Small Caps
01-Oct-19 Published by: Small Caps
Actinogen Medical announces ‘breakthrough’study results for Alzheimer’s drug Xanamem
01-Oct-19 Stockhead
01-Oct-19 Published by: Stockhead
Health: Actinogen recovers some hope from Xanamem wreckage
01-Oct-19 Pharmaceutical Daily News
01-Oct-19 Published by: Pharmaceutical Daily News
Actinogen Medical pleased with positive efficacy data for Xanamem in Alzheimer’s patients
01-Oct-19 Motley Fool
01-Oct-19 Published by: Motley Fool
Why Actinogen Medical shares climbed 466% on excitement over an Alzheimer’s treatment
03-Jul-19 Boardroom Media
03-Jul-19 Published by: Boardroom Media
ASX:ACW Xanamem Clinical Development & Investor Update
29-Jun-19 Finfeed
29-Jun-19 Published by: Finfeed
Cortisol inhibition – a potential new approach to treating Alzheimer’s disease
03-Jun-19 Bioshares
03-Jun-19 Published by: Bioshares
Edition 794: Actinogen Medical – Update on Higher Dose Safety Study
13-May-19 Bioshares
13-May-19 Published by: Bioshares
Edition 791: Actinogen – Phase II Study Dose Too Low
07-May-19 The World News
07-May-19 Published by: The World News
Actinogen shares crash after drug trial
07-May-19 nine.com.au Finance
07-May-19 Published by: nine.com.au Finance
Actinogen shares crash after drug trial
07-May-19 The Motley Fool
07-May-19 Published by: The Motley Fool
Actinogen Medical share price crashes 67% lower on Alzheimer’s study results
07-May-19 Investing.com
07-May-19 Published by: Investing.com
BRIEF-Actinogen Medical Updates On Phase II Alzheimer’s Disease Trial Results
07-May-19 NT News
07-May-19 Published by: NT News
Actinogen shares crash after drug trial
07-May-19 Mercury
07-May-19 Published by: Mercury
Actinogen shares crash after drug trial
07-May-19 Herald Sun
07-May-19 Published by: Herald Sun
Actinogen shares crash after drug trial
07-May-19 Kalkine Media
07-May-19 Published by: Kalkine Media
Actinogen Medical Released Alzheimer’s Disease Trial
07-May-19 Small Caps
07-May-19 Published by: Small Caps
Actinogen Medical phase two Alzheimer’s clinical trial disappoints
07-May-19 Biotech Dispatch
07-May-19 Published by: Biotech Dispatch
XanADu trial disappoints for Actinogen Medical
07-May-19 Stockhead
07-May-19 Published by: Stockhead
Health: Actinogen’s Alzheimer’s treatment comes up short, stock crashes 70pc
07-May-19 Yahoo Finance
07-May-19 Published by: Yahoo Finance
Actinogen Medical share price crashes 67% lower on Alzheimer’s study results
07-May-19 news.com.au
07-May-19 Published by: news.com.au
Actinogen shares crash after drug trial
07-May-19 Alzheimer Europe
07-May-19 Published by: Alzheimer Europe
Actinogen Medical announces results from its Phase II clinical trial XanADu in AD
14-Apr-19 The Today Show
14-Apr-19 Published by: The Today Show
Alzheimer’s breakthrough: New drug targets cortisol, the stress hormone in the brain
09-Apr-19 News.com.au
09-Apr-19 Published by: News.com.au
Aussie pill could hold cure for Alzheimer’s
08-Apr-19 7 News
08-Apr-19 Published by: 7 News
Alzheimer’s breakthrough could be just a pill away after medical trial in Perth
08-Apr-19 The West Australian
08-Apr-19 Published by: The West Australian
Perth trial gives hope for Alzheimer’s breakthrough
08-Apr-19 Perth Now
08-Apr-19 Published by: Perth Now
Perth trial gives hope for Alzheimer’s breakthrough
04-Apr-19 Biotech Dispatch
04-Apr-19 Published by: Biotech Dispatch
Actinogen appoints new director
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Video: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Podcast: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
25-Mar-19 Bioshares
25-Mar-19 Published by: Bioshares
A Local Investment Perspective
18-Mar-19 PharmiWeb.com
18-Mar-19 Published by: PharmiWeb.com
Edison initiates coverage on Actinogen Medical (ACW)
01-Mar-19 Neuro Central
01-Mar-19 Published by: Neuro Central
International Women’s Day: A day in the life of Tamara Miller
22-Feb-19 Boardroom Media
22-Feb-19 Published by: Boardroom Media
1st participant dosed in important new Xanamem study-XanaHES
30-Jan-19 BioWorld
30-Jan-19 Published by: BioWorld
Australian’s Actinogen tackles Alzheimer’s disease by inhibiting excess cortisol in the brain
04-Jan-19 Stockhead
04-Jan-19 Published by: Stockhead
Actinogen in the Stockhead 1000+ club – one of only six small cap healthcare companies to grow more than 1000 percent over the last decade
18-Dec-18 Cognitive Vitality
18-Dec-18 Published by: Cognitive Vitality
Does stress worsen cognitive functions?
08-Dec-18 The West Australian
08-Dec-18 Published by: The West Australian
Trial drug offers hope for Alzheimer’s treatment
28-Nov-18 Actinogen Medical
28-Nov-18 Published by: Actinogen Medical
Actinogen Medical XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Actinogen has achieved a major milestone through enrolling the final patient into XanADu, its landmark trial in Alzheimer’s disease. Find out more on XanADu, and Xanamem and cortisol in Alzheimer’s and other neurological diseases, with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board.
27-Nov-18 Biotech Dispatch
27-Nov-18 Published by: Biotech Dispatch
Final patient enrolled in Actinogen’s XanADu trial
26-Nov-18 Business Wire
26-Nov-18 Published by: Business Wire
Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting Stress Hormone Cortisol
25-Nov-18 Alzheimer Europe Science Watch
25-Nov-18 Published by: Alzheimer Europe Science Watch
Actinogen Medical completes recruitment of participants for its Phase II clinical trial of Xanamem for AD
20-Nov-18 Australian Financial Review (AFR)
20-Nov-18 Published by: Australian Financial Review (AFR)
Developing potential Alzheimer’s treatment
Investors eye new drug’s possibilities
01-Nov-18 BioPharma Dealmakers
01-Nov-18 Published by: BioPharma Dealmakers
Targeting cortisol to treat Alzheimer’s disease and cognitive impairment
01-Nov-18 Proactive Investors
01-Nov-18 Published by: Proactive Investors
Actinogen moves to next stage of Alzheimer’s treatment trials
31-Oct-18 Ch 9 News Online
31-Oct-18 Published by: Ch 9 News Online
Cortisol-blocking drug could slow Alzheimer’s
Actinogen Medical and Xanamem featured on national TV referencing our XanADu trial in Alzheimer’s disease. The trial has recruited the last patient and is on track to report out results in less than 8 months!
31-Oct-18 Ch 9 News
31-Oct-18 Published by: Ch 9 News
Stress could lead to dementia
Actinogen Medical and Xanamem featured on national TV referencing our XanADu trial in Alzheimer’s disease. The trial has recruited the last patient and is on track to report out results in less than 8 months!
01-Oct-18 Aged Care Weekly
01-Oct-18 Published by: Aged Care Weekly
Dispelling myths about Alzheimer’s disease
25-Sep-18 Finance News Network
25-Sep-18 Published by: Finance News Network
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
25-Sep-18 FNN Investor Event
25-Sep-18 Published by: FNN Investor Event
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
19-Sep-18 The Constant Investor
19-Sep-18 Published by: The Constant Investor
A biotech all about Alzheimer’s
10-Sep-18 Aged Care Weekly
10-Sep-18 Published by: Aged Care Weekly
How do we prepare for Dementia and Alzheimer’s?
07-Sep-18 Talking Business
07-Sep-18 Published by: Talking Business
Ep 30: Podcast interview with Leon Gettler & Dr Bill Ketelbey (Play from 1:00 to 16.50)
05-Sep-18 Stockhead
05-Sep-18 Published by: Stockhead
Why Actinogen’s progress is good news for Alzheimer’s patients and investors
16-Aug-18 Pharma In Focus
16-Aug-18 Published by: Pharma In Focus
Australian Alzheimer drug progresses
15-Aug-18 LabOnline
15-Aug-18 Published by: LabOnline
Patient enrolment for Alzheimer’s trial close to completion
15-Aug-18 Stockhead
15-Aug-18 Published by: Stockhead
Actinogen Hits Enrolment Milestone for Alzheimer’s Treatment Clinical Trial
09-Aug-18 Biotech Dispatch
09-Aug-18 Published by: Biotech Dispatch
Recognition for Actinogen Medical advisor
30-Jul-18 Stockhead
30-Jul-18 Published by: Stockhead
Actinogen to expand clinical development program of its novel Alzheimer’s drug
12-Jul-18 Stockhead
12-Jul-18 Published by: Stockhead
Actinogen is amping up patient recruitment for faster testing of novel Alzheimer’s drug
11-Jul-18 BBC News
11-Jul-18 Published by: BBC News
Dementia app firm MindMate teams up for clinical trial
11-Jul-18 Digit
11-Jul-18 Published by: Digit
MindMate Partners with Actinogen to Pioneer Alzheimer’s Research
03-Jul-18 Aged Care Weekly
03-Jul-18 Published by: Aged Care Weekly
Participating in clinical research benefits the individual and society as a whole
28-Jun-18 CommSec Executive Series
28-Jun-18 Published by: CommSec Executive Series
Dr Bill Ketelbey speaks with Tom Piotrowski about the company’s Ph II clinical trial for the treatment of Alzheimer’s disease
07-Jun-18 Stockhead
07-Jun-18 Published by: Stockhead
Actinogen presents Alzheimer’s trial data and more at world’s biggest biotech event
06-Jun-18 Proactive Investors
06-Jun-18 Published by: Proactive Investors
Actinogen Medical opens SPP after successful $15 million placement
31-May-18 Proactive Investors
31-May-18 Published by: Proactive Investors
Actinogen Medical presenting success with Xanamem at BIO International
30-May-18 Aged Care Weekly
30-May-18 Published by: Aged Care Weekly
Xanamem drug: A step forward for Alzheimer’s disease
24-May-18 Biotech Dispatch
24-May-18 Published by: Biotech Dispatch
Positive news for Australian company Actinogen
24-May-18 SkyNews.com.au
24-May-18 Published by: SkyNews.com.au
Business | Tech.Biz | VIEW FROM 16:49
Actinogen Medical announces $15 million capital raise
23-May-18 Small Caps
23-May-18 Published by: Small Caps
Actinogen Medical attracts US biotech investor as Alzheimer’s XanADu study remains on track
23-May-18 Business News Australia
23-May-18 Published by: Business News Australia
Alzheimer’s research company secures capital raising on promising trials
23-May-18 Rat’s Rant
23-May-18 Published by: Rat’s Rant
The Mafia Edition
23-May-18 The Australian
23-May-18 Published by: The Australian
Actinogen wins backing for Alzheimer’s treatment trial
23-May-18 Stockhead
23-May-18 Published by: Stockhead
Actinogen’s Alzheimer’s trial gets independent tick of approval; raises $15m
14-May-18 Stockhead
14-May-18 Published by: Stockhead
Blockchain could be a game changer in medical clinical trials, says top expert
13-May-18 Daily Mail
13-May-18 Published by: Daily Mail
Being a medical guinea pig could help Alzheimer’s patients stay a step ahead of the memory robbing disease
08-May-18 Aged Care Weekly
08-May-18 Published by: Aged Care Weekly
Have we been looking at Alzheimer’s disease the wrong way?
02-May-18 Proactive Investors
02-May-18 Published by: Proactive Investors
Actinogen Medical attracts $15 million to progress Alzheimer’s disease therapy
19-Apr-18 Stockhead
19-Apr-18 Published by: Stockhead
Alzheimer’s treatment failures are an opportunity for Actinogen
23-Mar-18 The Age
23-Mar-18 Published by: The Age
What if we have got it wrong on Alzheimer’s?
23-Mar-18 The Sydney Morning Herald
23-Mar-18 Published by: The Sydney Morning Herald
What if we have got it wrong on Alzheimer’s?
21-Mar-18 Small Caps
21-Mar-18 Published by: Small Caps
Actinogen moves towards XanADu starting line to treat Alzheimer’s disease
21-Mar-18 Stockhead
21-Mar-18 Published by: Stockhead
Major Milestone: Actinogen’s Alzheimer’s trial passes half-way point
16-Mar-18 Aged Care Weekly
16-Mar-18 Published by: Aged Care Weekly
Things you didn’t know about your brain
27-Feb-18 Daily Mail
27-Feb-18 Published by: Daily Mail
Could anti-stress drug help beat Alzheimers? Scientists have failed to find a treatment for the disease after decades of research
19-Feb-18 Stockhead
19-Feb-18 Published by: Stockhead
Actinogen on track with Alzheimer’s trial as research falls into line
16-Feb-18 Rat’s Rant
16-Feb-18 Published by: Rat’s Rant
What’s Doing
12-Feb-18 Rat’s Rant
12-Feb-18 Published by: Rat’s Rant
What’s Hot
12-Feb-18 Stockhead
12-Feb-18 Published by: Stockhead
Aussie biotech Actinogen is testing a unique treatment for Alzheimer’s
06-Feb-18 Biotech Daily
06-Feb-18 Published by: Biotech Daily
ACW: Research Backs Stress, Cognitive Decline Link
29-Jan-18 Stockhead
29-Jan-18 Published by: Stockhead
Actinogen hopes Alzheimer’s trial can beat global 99.6pc failure rate
25-Jan-18 Biotech Daily
25-Jan-18 Published by: Biotech Daily
Dr Boreham’s Crucible: Actinogen Medical
04-Jan-18 The West Australian
04-Jan-18 Published by: The West Australian
Researchers confident stress drug could be Alzheimer’s breakthrough
09-Dec-17 The Mercury
09-Dec-17 Published by: The Mercury
Talking Point: The more drugs we trial, the closer we get
08-Dec-17 nestegg.com.au
08-Dec-17 Published by: nestegg.com.au
‘Alarm call’: dementia incidences to triple by 2050
06-Dec-17 Australian Financial Review
06-Dec-17 Published by: Australian Financial Review
Actinogen Medical raises $5.2m for Alzheimer’s treatment
09-Nov-17 The Motley Fool
09-Nov-17 Published by: The Motley Fool
2 exciting biotech shares to watch in 2018
07-Nov-17 Biotech Dispatch
07-Nov-17 Published by: Biotech Dispatch
Amgen veteran joins Actinogen
31-Oct-17 Australasian Biotechnology
31-Oct-17 Published by: Australasian Biotechnology
The Journal of AusBiotech | Oct 2017 | Vol 27 | Number 3: A new approach to Alzheimer’s disease
31-Oct-17 The Senior
31-Oct-17 Published by: The Senior
What will it take to find a cure for Alzheimer’s disease?
26-Oct-17 Aged Care Insite
26-Oct-17 Published by: Aged Care Insite
Why we need new treatments to beat Alzheimer’s
24-Oct-17 Hot Copper / BIG Business News & Finance
24-Oct-17 Published by: Hot Copper / BIG Business News & Finance
Australian Microcap Investment Conference: Interview with Dr Bill Ketelbey
09-Jul-17 Channel 9 News National
09-Jul-17 Published by: Channel 9 News National
Breakthrough Alzheimer’s medication could ‘make a difference’ in just three months
09-Jul-17 Sunday Times Perth
09-Jul-17 Published by: Sunday Times Perth
Crucial WA Test: Is this the Alzheimer’s breakthrough the world has been waiting for?
22-Jun-17 9 Finance: Business News
22-Jun-17 Published by: 9 Finance: Business News
Actinogen enrols US patients for XanADu
23-May-17 Lab Online
23-May-17 Published by: Lab Online
Blocking the stress hormone: Phase II Alzheimer’s trial underway
22-May-17 ABC Central
22-May-17 Published by: ABC Central
First patient from Central Coast
18-May-17 Biotech Dispatch
18-May-17 Published by: Biotech Dispatch
Actinogen Medical starts Phase 2 trial for Alzheimer’s therapy
17-May-17 Pharmacy Daily
17-May-17 Published by: Pharmacy Daily
Xanamem AD trials
16-May-17 Proactive Investors
16-May-17 Published by: Proactive Investors
Actinogen Medical begins landmark Alzheimer’s disease clinical trial
16-May-17 Biotech Daily
16-May-17 Published by: Biotech Daily
Actinogen Treats 1st Xanamem Alzheimer’s Patient
10-May-17 The Daily Edition
10-May-17 Published by: The Daily Edition
Alzheimer’s trial targeting stress hormone
10-May-17 The Australian Financial Review (AFR)
10-May-17 Published by: The Australian Financial Review (AFR)
Australian Firm Treads New Path On Alzheimer’s
27-Mar-17 Herald Sun
27-Mar-17 Published by: Herald Sun
New trial offers hope on dementia
27-Mar-17 The West Australian
27-Mar-17 Published by: The West Australian
Human drug trial key to beat Alzheimer’s
27-Mar-17 The Daily Telegraph
27-Mar-17 Published by: The Daily Telegraph
Trial go-ahead for new Alzheimer’s drug
27-Mar-17 The Advertiser
27-Mar-17 Published by: The Advertiser
Dementia drug trial will give new hope
27-Mar-17 Geelong Advertiser
27-Mar-17 Published by: Geelong Advertiser
Trial to test promising drug for treating Alzheimer’s disease
27-Mar-17 Townsville Bulletin
27-Mar-17 Published by: Townsville Bulletin
Alzheimer’s drug hope
27-Mar-17 The Mercury
27-Mar-17 Published by: The Mercury
Drug trial starts to tackle one of nation’s biggest killers
27-Mar-17 NT News
27-Mar-17 Published by: NT News
Trial for new Alzheimer’s pill
27-Mar-17 Gold Coast Bulletin
27-Mar-17 Published by: Gold Coast Bulletin
New drug offers hope
26-Mar-17 Herald Sun
26-Mar-17 Published by: Herald Sun
‘Blockbuster’ Alzheimer’s drug Xanamem to be tested on Australian patients
07-Feb-17 British Journal of Pharmacology: Research Paper
07-Feb-17 Published by: British Journal of Pharmacology: Research Paper
Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)
01-Feb-17 Actinogen Medical
01-Feb-17 Published by: Actinogen Medical
Professor Colin Masters receives Australia Day Honours
29-Sep-16 Wholesale Investor
29-Sep-16 Published by: Wholesale Investor
Dr Bill Ketelbey Interview
26-Sep-16 The World Loves Melbourne
26-Sep-16 Published by: The World Loves Melbourne
Understanding Alzheimer’s Conference at Novotel Melbourne
24-Aug-16 NextBiotech
24-Aug-16 Published by: NextBiotech
ACW Starts Phase II Clinical Trials: Major Milestone Set to Unlock Value Uplift?
29-Jul-16 Herald Sun
29-Jul-16 Published by: Herald Sun
Australian Drug to be trialled in bid to stop Alzheimer’s disease
28-Jul-16 IT Wire
28-Jul-16 Published by: IT Wire
Aussie company developing ‘landmark’ drug as potential treatment for Alzheimer’s
28-Jul-16 The Australian
28-Jul-16 Published by: The Australian
Alzheimer’s research offers hope
27-Jul-16 BusinessWire
27-Jul-16 Published by: BusinessWire
Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer’s Disease
08-Jun-16 FinFeed
08-Jun-16 Published by: FinFeed
FDA Feedback puts Actinogen’s phase II trial one step closer to US approval
08-Jun-16 NextBiotech
08-Jun-16 Published by: NextBiotech
Multi-Billion Alzheimer’s Drug Development Boom Underway: ACW Well Positioned in Phase II Trials
08-Jun-16 BioTech Daily
08-Jun-16 Published by: BioTech Daily
FDA Enhances Phase II Xanamem Alzheimer’s Trial
08-Jun-16 Wholesale Investor
08-Jun-16 Published by: Wholesale Investor
Actinogen Receives US FDA Feedback to Enhance Alzheimers Study
20-Apr-16 NextBiotech
20-Apr-16 Published by: NextBiotech
Ex Pfizer VP to Repeat Market Topping Drug Development with this ASX stock?
18-Nov-15 Finance News Network
18-Nov-15 Published by: Finance News Network
Actinogen discusses Xanamem Phase 1 results
06-Oct-15 Proactive Investors
06-Oct-15 Published by: Proactive Investors
Actinogen Medical on track with Alzheimer’s Drug
28-Sep-15 Proactive Investors
28-Sep-15 Published by: Proactive Investors
Actinogen readies to reveal clinical data
01-May-15 AFR
01-May-15 Published by: AFR
Alzheimer’s cure behind the boom in brain science
27-Apr-15 Herald Sun
27-Apr-15 Published by: Herald Sun
Victorian trial to treat early-stage Alzheimer’s by reducing brain’s stress hormone levels
24-Apr-15 Proactive Investors
24-Apr-15 Published by: Proactive Investors
Actinogen Medical raises $10M for Alzheimer’s drug trial
Date Published By Headline
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call 19 Oct 2020: Audio only
Dr Bill Ketelbey provides an update on the clinical development plans “Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases”
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call 19 Oct 2020: Webcast presentation
Dr Bill Ketelbey provides an update on the clinical development plans “Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases”
30-Oct-19 Boardroom Media
30-Oct-19 Published by: Boardroom Media
ASX:ACW Market update October 2019: Will Canty speaks to Bill Ketelbey at 10th Annual Australian Microcap Investment Conference
22-Oct-19 Morgans Financial Limited
22-Oct-19 Published by: Morgans Financial Limited
Under The Microscope Podcast: Morgans Senior Analyst Scott Power interview with Dr Bill Ketelbey explaining recent clinical trial results and the path forward for Xanamem
01-Oct-19 Actinogen Medical
01-Oct-19 Published by: Actinogen Medical
Conference Call Audio: 1 Oct 2019 Cognitive improvement demonstrated with Xanamem
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Video: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Podcast: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
20-Mar-19 Edison TV
20-Mar-19 Published by: Edison TV
Executive Interview with Dr Bill Ketelbey, CEO, Actinogen Medical
07-Sep-18 Talking Business
07-Sep-18 Published by: Talking Business
Ep 30: Podcast interview with Leon Gettler & Dr Bill Ketelbey (Play from 1:00 to 16.50)
28-Jun-18 CommSec Executive Series
28-Jun-18 Published by: CommSec Executive Series
Dr Bill Ketelbey speaks with Tom Piotrowski about the company’s Ph II clinical trial for the treatment of Alzheimer’s disease
30-May-18 Open Briefing
30-May-18 Published by: Open Briefing
Investor Conference Call Transcript: 30 May 2018
30-May-18 Actinogen Medical
30-May-18 Published by: Actinogen Medical
Investor Conference Call Audio: 30 May 2018
29-Sep-16 Wholesale Investor
29-Sep-16 Published by: Wholesale Investor
Dr Bill Ketelbey Interview
Date Published By Headline
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call 19 Oct 2020: Webcast presentation
Dr Bill Ketelbey provides an update on the clinical development plans “Developing novel therapies for cognitive impairment and behavioural symptoms due to raised cortisol in chronic neurological, psychiatric, developmental and metabolic diseases”
08-Sep-20 ASX
08-Sep-20 Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020): Actinogen Medical (ASX:ACW) pre-recorded presentation with Dr Bill Ketelbey
31-Jul-20 Finance News Network
31-Jul-20 Published by: Finance News Network
FNN CEO Showcase: Actinogen Medical (ASX:ACW) Presentation, FNN Online Investor Event, July 2020
15-Jun-20 Actinogen Medical
15-Jun-20 Published by: Actinogen Medical
Bio Digital 2020: Company presentation and audio. Dr Bill Ketelbey provides company update “Developing innovative treatments for cognitive impairment associated with neurological and metabolic diseases due to raised cortisol, including Alzheimer’s disease”
29-Jan-20 Sachs TV
29-Jan-20 Published by: Sachs TV
3rd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey, CEO Actinogen Medical Ltd presentation in San Francisco, USA
25-Nov-19 Actinogen Medical
25-Nov-19 Published by: Actinogen Medical
AGM 2019: Managing Directors Address to Shareholders
22-Nov-19 Edison TV
22-Nov-19 Published by: Edison TV
Executive Interview – Actinogen Medical CEO, Dr Bill Ketelbey, provides an update on recent developments, R&D progress and expected newsflow
08-Nov-19 Stockhead TV
08-Nov-19 Published by: Stockhead TV
90 Seconds with… Actinogen Medical. Dr Bill Ketelbey tells us about his AusBiotech Invest presentation and upcoming newsflow
06-Nov-19 Small Caps
06-Nov-19 Published by: Small Caps
Australian Microcap Investment Conference 2019: Actinogen Medical presentation
30-Oct-19 Boardroom Media
30-Oct-19 Published by: Boardroom Media
ASX:ACW Market update October 2019: Will Canty speaks to Bill Ketelbey at 10th Annual Australian Microcap Investment Conference
14-Apr-19 The Today Show
14-Apr-19 Published by: The Today Show
Alzheimer’s breakthrough: New drug targets cortisol, the stress hormone in the brain
08-Apr-19 7 News
08-Apr-19 Published by: 7 News
Alzheimer’s breakthrough could be just a pill away after medical trial in Perth
08-Apr-19 The West Australian
08-Apr-19 Published by: The West Australian
Perth trial gives hope for Alzheimer’s breakthrough
08-Apr-19 Perth Now
08-Apr-19 Published by: Perth Now
Perth trial gives hope for Alzheimer’s breakthrough
28-Mar-19 Morgans Financial Limited
28-Mar-19 Published by: Morgans Financial Limited
Under the Microscope Video: Morgans Senior Analyst Scott Power, interviewed Dr Bill Ketelbey, CEO & Managing Director of Actinogen Medical
20-Mar-19 Edison TV
20-Mar-19 Published by: Edison TV
Executive Interview with Dr Bill Ketelbey, CEO, Actinogen Medical
22-Feb-19 Boardroom Media
22-Feb-19 Published by: Boardroom Media
1st participant dosed in important new Xanamem study-XanaHES
06-Jan-19 Sachs TV
06-Jan-19 Published by: Sachs TV
2nd Annual SACHS Neuroscience Innovation Forum: Dr Bill Ketelbey presentation in San Francisco, USA
28-Nov-18 Actinogen Medical
28-Nov-18 Published by: Actinogen Medical
Actinogen Medical XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Actinogen has achieved a major milestone through enrolling the final patient into XanADu, its landmark trial in Alzheimer’s disease. Find out more on XanADu, and Xanamem and cortisol in Alzheimer’s and other neurological diseases, with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board.
31-Oct-18 Ch 9 News Online
31-Oct-18 Published by: Ch 9 News Online
Cortisol-blocking drug could slow Alzheimer’s
Actinogen Medical and Xanamem featured on national TV referencing our XanADu trial in Alzheimer’s disease. The trial has recruited the last patient and is on track to report out results in less than 8 months!
31-Oct-18 Ch 9 News
31-Oct-18 Published by: Ch 9 News
Stress could lead to dementia
Actinogen Medical and Xanamem featured on national TV referencing our XanADu trial in Alzheimer’s disease. The trial has recruited the last patient and is on track to report out results in less than 8 months!
12-Oct-18 Spark Plus
12-Oct-18 Published by: Spark Plus
Healthcare Investor Day
25-Sep-18 Finance News Network
25-Sep-18 Published by: Finance News Network
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
25-Sep-18 FNN Investor Event
25-Sep-18 Published by: FNN Investor Event
Actinogen Medical (ASX:ACW) Phase II Alzheimer’s trials
07-Sep-18 Talking Business
07-Sep-18 Published by: Talking Business
Ep 30: Podcast interview with Leon Gettler & Dr Bill Ketelbey (Play from 1:00 to 16.50)
28-Jun-18 CommSec Executive Series
28-Jun-18 Published by: CommSec Executive Series
Dr Bill Ketelbey speaks with Tom Piotrowski about the company’s Ph II clinical trial for the treatment of Alzheimer’s disease
24-May-18 SkyNews.com.au
24-May-18 Published by: SkyNews.com.au
Business | Tech.Biz | VIEW FROM 16:49
Actinogen Medical announces $15 million capital raise
05-Apr-18 Actinogen Medical
05-Apr-18 Published by: Actinogen Medical
Investor Open Briefing March 2018: Dr Bill Ketelbey, CEO, and Dr Geoff Brooke, Chairman, presented at the Investor Briefing in Sydney providing an update on Actinogen Medical and the exciting developments with Xanamem in Alzheimer’s disease
29-Nov-17 Actinogen Medical
29-Nov-17 Published by: Actinogen Medical
Actinogen Medical & KaRa Minds: Leading Alzheimer’s Researchers Address to Shareholders
Dr Bill Ketelbey speaks with Prof Ralph Martins and Associate Prof Kathryn Goozee from KaRa Minds following the Actinogen Medical AGM
28-Nov-17 Ted.com
28-Nov-17 Published by: Ted.com
Elizabeth Blackburn at TED2017: The science of cells that never get old
24-Oct-17 Hot Copper / BIG Business News & Finance
24-Oct-17 Published by: Hot Copper / BIG Business News & Finance
Australian Microcap Investment Conference: Interview with Dr Bill Ketelbey
09-Jul-17 Channel 9 News National
09-Jul-17 Published by: Channel 9 News National
Breakthrough Alzheimer’s medication could ‘make a difference’ in just three months
29-Sep-16 Wholesale Investor
29-Sep-16 Published by: Wholesale Investor
Dr Bill Ketelbey Interview
18-Nov-15 Finance News Network
18-Nov-15 Published by: Finance News Network
Actinogen discusses Xanamem Phase 1 results
Date Published By Headline
19-Nov-19 Actinogen Medical
19-Nov-19 Published by: Actinogen Medical
Investor Newsletter: Nov 2019
16-Apr-19 Actinogen Medical
16-Apr-19 Published by: Actinogen Medical
Investor Newsletter: Apr 2019
12-Dec-18 Actinogen Medical
12-Dec-18 Published by: Actinogen Medical
Investor Newsletter: Dec 2018
12-Oct-17 Actinogen Medical
12-Oct-17 Published by: Actinogen Medical
Investor Newsletter: October 2017
16-Mar-17 Actinogen Medical
16-Mar-17 Published by: Actinogen Medical
Quarterly Newsletter: Mar 2017
31-Aug-16 Actinogen Medical
31-Aug-16 Published by: Actinogen Medical
Investor Update: Issue 5
01-Dec-15 Actinogen Medical
01-Dec-15 Published by: Actinogen Medical
Investor Update: Issue 4
17-Aug-15 Actinogen Medical
17-Aug-15 Published by: Actinogen Medical
Investor Update: Issue 3
15-Apr-15 Actinogen Medical
15-Apr-15 Published by: Actinogen Medical
Investor Update: Issue 2
16-Feb-15 Actinogen Medical
16-Feb-15 Published by: Actinogen Medical
Investor Update: Issue 1
Date Published By Headline
28-Oct-20 Monsoon Communications
28-Oct-20 Published by: Monsoon Communications
UPCOMING: Morning Twilight Investor Briefing 11:00am to 11:40am
Register to attend
19-Oct-20 Actinogen Medical
19-Oct-20 Published by: Actinogen Medical
Actinogen Medical Conference Call (19 Oct 2020 at 11.00am AEDT)
08-Sep-20 ASX
08-Sep-20 Published by: ASX
ASX Small & Mid-Cap Conference (8-10 Sep 2020)
28-Jul-20 Finance News Network
28-Jul-20 Published by: Finance News Network
FNN CEO Showcase: Sydney (28 Jul 2020) Virtual Event
27-Jul-20 Alzheimer’s Association
27-Jul-20 Published by: Alzheimer’s Association
Alzheimer’s Association International Conference (AAIC) Virtual Event (27-31 Jul 2020)
08-Jun-20 Biotechnology Innovation Organization
08-Jun-20 Published by: Biotechnology Innovation Organization
BIO Digital 2020: Virtual (8-12 Jun 2020)
02-Apr-20 Kenes Group
02-Apr-20 Published by: Kenes Group
Advances in Alzheimer’s and Parkinson’s Therapies An AAT-AD/PD Focus Meeting: Virtual (2-5 Apr 2020)
12-Jan-20 Sachs Associates
12-Jan-20 Published by: Sachs Associates
3rd Annual Nueroscience Innovation Forum: San Francisco USA (12 Jan 2020)
12-Jan-20 Pyschosis Australia Trust
12-Jan-20 Published by: Pyschosis Australia Trust
Australian Psychosis Symposium 2020 (12 Jan 2020)
11-Jan-20 J.P. Morgan
11-Jan-20 Published by: J.P. Morgan
38th Annual Healthcare Conference: San Francisco USA (13-16 Jan 2020)
04-Dec-19 CTAD Congress
04-Dec-19 Published by: CTAD Congress
CTAD 2019 (4-7 Dec 2019)
31-Oct-19 AusBiotech Investment
31-Oct-19 Published by: AusBiotech Investment
Australia Biotech Invest & Partnering 2019 (31 Oct 2019)
30-Oct-19 AusBiotech
30-Oct-19 Published by: AusBiotech
AusBiotech 2019 (30 Oct – 1 Nov 2019)
27-Oct-19 QUT
27-Oct-19 Published by: QUT
The Bridge Program (27-29 Oct 2019)
22-Oct-19 Australian Microcap
22-Oct-19 Published by: Australian Microcap
10th Annual Australian Microcap Investment Conference (22-23 Oct 2019)
11-Oct-19 AC4R
11-Oct-19 Published by: AC4R
Annual Scientific Meeting: Sydney (11 Oct 2019)
25-Sep-19 Alzheimer’s Association
25-Sep-19 Published by: Alzheimer’s Association
AAIC Satellite Sydney Symposium: Sydney (25-27 Sep 2019)
19-Aug-19 Informa Connect
19-Aug-19 Published by: Informa Connect
Bio Connections Australia: Melbourne (19-20 Aug 2019)
26-Jul-19 Bioshares
26-Jul-19 Published by: Bioshares
2019 Bioshares Biotech Summit: Queenstown NZ (26-27 Jul 2019)
03-Jun-19 Biotechnology Innovation Organization
03-Jun-19 Published by: Biotechnology Innovation Organization
Bio 2019, Philadelphia, USA (3-6 Jun 2019)
07-Jan-19 J.P. Morgan
07-Jan-19 Published by: J.P. Morgan
37th Annual J.P. Morgan Healthcare Conference San Francisco USA (7-10 Jan 2019)
06-Jan-19 Sachs Associates
06-Jan-19 Published by: Sachs Associates
2nd Annual SACHS Neuroscience Innovation Forum San Francisco USA (6 Jan 2019)
24-Oct-18 CTAD Congress
24-Oct-18 Published by: CTAD Congress
CTAD Barcelona, Spain (24-27 Oct 2018)
17-Oct-18 Australian Microcap
17-Oct-18 Published by: Australian Microcap
Australian Microcap Investment Conference Melbourne, Australia (17 Oct 2018)
12-Oct-18 AC4R
12-Oct-18 Published by: AC4R
Annual Scientific Meeting Sydney, Australia (12 Oct 2018)
10-Oct-18 AusBiotech Investment
10-Oct-18 Published by: AusBiotech Investment
Australia Biotech Invest & Partnering, Melbourne (30 Oct 2018)
18-Sep-18 Finance News Network
18-Sep-18 Published by: Finance News Network
FNN Investor Event, Sydney Australia (18 Sep 2018)
12-Sep-18 Spark Plus
12-Sep-18 Published by: Spark Plus
Healthcare Investor Day, Singapore (12 Sep 2018)
27-Jul-18 Bioshares
27-Jul-18 Published by: Bioshares
Bioshares Biotech Summit 2018 Queenstown, NZ (27-28 Jul 2018)
22-Jul-18 Alzheimer’s Association
22-Jul-18 Published by: Alzheimer’s Association
AAIC 2018 Chicago, USA (22-26 Jul 2018)
04-Jun-18 Biotechnology Innovation Organization
04-Jun-18 Published by: Biotechnology Innovation Organization
BIO International Convention Boston, USA (4-7 Jun 2018)
08-Jan-18 J.P. Morgan
08-Jan-18 Published by: J.P. Morgan
J.P. Morgan Healthcare Conference San Francisco USA (8-11 Jan 2018)
25-Oct-17 AusBiotech
25-Oct-17 Published by: AusBiotech
AusBiotech 2017 Adelaide, Australia (25-27 Oct 2017)
24-Oct-17 AusBiotech Investment
24-Oct-17 Published by: AusBiotech Investment
Australia Biotech Invest 2017 Melbourne, Australia (24 Oct 2017)
17-Oct-17 AAIC
17-Oct-17 Published by: AAIC
Alzheimer’s Australia Biennial National Dementia Conference Melbourne, Australia (17-20 Oct 2017)
17-Oct-17 Australian Microcap
17-Oct-17 Published by: Australian Microcap
8th Annual Australian Microcap Investment Melbourne, Australia (17-18 Oct 2017)
17-Oct-17 AC4R
17-Oct-17 Published by: AC4R
AC4R Conference Melbourne, Australia (17 Oct 2017)
21-Jul-17 Bioshares
21-Jul-17 Published by: Bioshares
Bioshares Biotech 2017 Summit Queenstown, NZ (21-22 Jul 2017)
19-Jun-17 Biotechnology Innovation Organization
19-Jun-17 Published by: Biotechnology Innovation Organization
Bio International Convention San Diego, USA (19-22 Jun 2017)
24-Oct-16 AusBiotech
24-Oct-16 Published by: AusBiotech
AusBiotech 2016 Melbourne, Australia (24-27 Oct 2016)
28-Jul-16 Bioshares
28-Jul-16 Published by: Bioshares
BioShares Biotechnology Summit Queenstown, NZ (28-29 Jul 2016)
22-Jul-16 Alzheimer’s Association
22-Jul-16 Published by: Alzheimer’s Association
AAIC Toronto, Canada (22-28 Jul 2016)
31-May-16 AC4R
31-May-16 Published by: AC4R
AC4R Conference Cairns, Australia (31 May 2016)
10-May-16 EBD Group
10-May-16 Published by: EBD Group
BioEquity Copenhagen, Denmark (10-11 May 2016)
06-May-16 Wholesale Investor
06-May-16 Published by: Wholesale Investor
WI Small Cap Showcase Sydney, Australia (6 May 2016)